Plasmodium falciparum FIKK 9.1 kinase modeling to screen and identify potent antimalarial agents from chemical library

The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite...

Full description

Saved in:
Bibliographic Details
Published in:3 Biotech Vol. 13; no. 8; p. 277
Main Authors: Kumar, D. Anil, Karjee, Pallab, Prasad, M. Rajendra, Punniyamurthy, Tharmalingam, Trivedi, Vishal
Format: Journal Article
Language:English
Published: Cham Springer International Publishing 01-08-2023
Springer Nature B.V
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite’s proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC 50 of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC 50 of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant ( K d ) is measured to be 27.8 ± 2.07 μM with a stoichiometry of n  = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials.
AbstractList The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite’s proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC50 of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC50 of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant (Kd) is measured to be 27.8 ± 2.07 μM with a stoichiometry of n = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials.
The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite's proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC50 of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC50 of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant (Kd) is measured to be 27.8 ± 2.07 μM with a stoichiometry of n = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials.The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite's proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC50 of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC50 of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant (Kd) is measured to be 27.8 ± 2.07 μM with a stoichiometry of n = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials.The online version contains supplementary material available at 10.1007/s13205-023-03677-x.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13205-023-03677-x.
The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite’s proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC 50 of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC 50 of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant ( K d ) is measured to be 27.8 ± 2.07 μM with a stoichiometry of n  = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials.
The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite's proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant ( ) is measured to be 27.8 ± 2.07 μM with a stoichiometry of  = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials. The online version contains supplementary material available at 10.1007/s13205-023-03677-x.
ArticleNumber 277
Author Punniyamurthy, Tharmalingam
Kumar, D. Anil
Karjee, Pallab
Trivedi, Vishal
Prasad, M. Rajendra
Author_xml – sequence: 1
  givenname: D. Anil
  surname: Kumar
  fullname: Kumar, D. Anil
  organization: Malaria Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati
– sequence: 2
  givenname: Pallab
  surname: Karjee
  fullname: Karjee, Pallab
  organization: Department of Chemistry, Indian Institute of Technology Guwahati
– sequence: 3
  givenname: M. Rajendra
  surname: Prasad
  fullname: Prasad, M. Rajendra
  organization: Malaria Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati
– sequence: 4
  givenname: Tharmalingam
  surname: Punniyamurthy
  fullname: Punniyamurthy, Tharmalingam
  organization: Department of Chemistry, Indian Institute of Technology Guwahati
– sequence: 5
  givenname: Vishal
  orcidid: 0000-0003-2520-6083
  surname: Trivedi
  fullname: Trivedi, Vishal
  email: vtrivedi@iitg.ernet.in, Vishalash_1999@yahoo.com
  organization: Malaria Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37476548$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1vFDEMhiNUREvpH-CAInHhMiWfm8wJoYpC1UpwAIlb5E0y25SZZElmq-6_x2XL8nEgl1j249e23qfkIJccCXnO2SlnzLxuXAqmOyZkx-TCmO7uETkSvGedNtIe7GPx9ZCctHbD8Gmue86ekENplFloZY_I7acR2lRC2kx0gNGnNVQMzy8uL2l_yum3lKFFikQcU17RudDma4yZQg40hZjnNGzpuswYYW5OE4xQE4wUVphqdKhlov46TsljckzLCnX7jDzGaS2ePPzH5Mv5u89nH7qrj-8vzt5edV6JxdzZyJU0EgYTg_U-iqh5EAp09CAGrmwf2LCwKoDA84zRPoCSg4flUkMYtDwmb3a6681yisHjRhVGt664Zt26Asn9Xcnp2q3KreNMaiX5vcKrB4Vavm9im92Umo_jCDmWTXPCKo4mWM4RffkPelM2NeN9SMleWml7gZTYUb6W1moc9ttw5u6tdTtrHaq6n9a6O2x68ecd-5ZfRiIgd0DDUl7F-nv2f2R_AMO7s7M
Cites_doi 10.1186/s12936-016-1408-1
10.1186/1471-2164-5-79
10.1093/trstmh/tru101
10.1038/nrmicro.2017.161
10.1056/NEJMc1713777
10.1371/journal.pone.0011747
10.1021/jm501603h
10.2174/1570180815666180727121200
10.1038/ncomms16044
10.1021/acsomega.7b00997
10.1016/j.bbrc.2020.05.154
10.1038/s41564-020-0702-4
10.1111/j.1742-4658.2007.05997.x
10.1111/j.1365-2141.2011.08755.x
10.3390/tropicalmed4010026
10.1111/bjh.16219
10.1016/j.bioorg.2017.09.011
10.1182/blood-2014-06-583054
10.1021/acsinfecdis.0c00724
10.1101/cshperspect.a025619
ContentType Journal Article
Copyright King Abdulaziz City for Science and Technology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Copyright_xml – notice: King Abdulaziz City for Science and Technology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
DBID NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1007/s13205-023-03677-x
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

PubMed

DeliveryMethod fulltext_linktorsrc
Discipline Economics
Chemistry
Agriculture
EISSN 2190-5738
ExternalDocumentID 10_1007_s13205_023_03677_x
37476548
Genre Journal Article
GroupedDBID -A0
-EM
0R~
2VQ
4.4
406
40G
8AO
8FE
8FG
8FH
AAAVM
AAFGU
AAHNG
AANZL
AAPBV
AATNV
AATVU
AAUYE
AAYFA
ABDBF
ABDZT
ABECU
ABFGW
ABFTV
ABJCF
ABJNI
ABJOX
ABKAS
ABKCH
ABMQK
ABSXP
ABTEG
ABTKH
ABTMW
ABXPI
ACBMV
ACBRV
ACBYP
ACGFS
ACHSB
ACIGE
ACIPQ
ACIWK
ACMLO
ACOKC
ACPRK
ACTTH
ACVWB
ACWMK
ADBBV
ADDVE
ADHHG
ADINQ
ADKNI
ADKPE
ADMDM
ADOXG
ADRAZ
ADTPH
ADURQ
ADYFF
ADZKW
AEFTE
AEGXH
AEJRE
AENEX
AEOHA
AEPYU
AESKC
AESTI
AEVLU
AEVTX
AEXYK
AFGXO
AFKRA
AFNRJ
AFQWF
AGDGC
AGGBP
AGJBK
AGMZJ
AHBYD
AHSBF
AHYZX
AIAKS
AILAN
AIMYW
AITGF
AJDOV
AJRNO
AJZVZ
AKQUC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOIJS
AXYYD
BBNVY
BENPR
BGLVJ
BGNMA
BHPHI
C24
C6C
CCPQU
CSCUP
DNIVK
DPUIP
EBLON
EBS
EIOEI
EJD
FERAY
FFXSO
FINBP
FNLPD
FSGXE
GGCAI
GJIRD
GX1
H4N
HCIFZ
HYE
HZ~
IKXTQ
IWAJR
J-C
JZLTJ
KOV
KQ8
L6V
LK8
LLZTM
M48
M4Y
M7P
M7S
M~E
NPVJJ
NQJWS
NU0
O9-
O9J
OK1
PT4
PTHSS
RNS
RPM
RSV
SCM
SISQX
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
STPWE
TSG
U2A
UOJIU
UTJUX
UZXMN
VFIZW
Z5O
Z7U
Z7V
Z7W
Z7Y
Z7Z
Z83
ZMTXR
53G
AACDK
AAHBH
AAJBT
AASML
ABAKF
ACAOD
ACDTI
ACZOJ
AEFQL
AEMSY
AFBBN
AGQEE
AGRTI
AIGIU
FIGPU
NPM
ROL
SJYHP
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c426t-8e14373af7ed8cce2e51d24a5eca2f1489d0f684da2000775cda43fcabb5adf53
IEDL.DBID RPM
ISSN 2190-572X
IngestDate Tue Sep 17 21:28:51 EDT 2024
Sat Oct 26 04:30:59 EDT 2024
Thu Oct 10 16:46:23 EDT 2024
Thu Nov 21 22:56:56 EST 2024
Sat Nov 02 12:29:51 EDT 2024
Sat Dec 16 12:04:40 EST 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Malaria
Lead identification and antimalarial
FIKK kinase
Language English
License King Abdulaziz City for Science and Technology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c426t-8e14373af7ed8cce2e51d24a5eca2f1489d0f684da2000775cda43fcabb5adf53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-2520-6083
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354315
PMID 37476548
PQID 2839383892
PQPubID 2034528
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10354315
proquest_miscellaneous_2841023811
proquest_journals_2839383892
crossref_primary_10_1007_s13205_023_03677_x
pubmed_primary_37476548
springer_journals_10_1007_s13205_023_03677_x
PublicationCentury 2000
PublicationDate 2023-08-01
PublicationDateYYYYMMDD 2023-08-01
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-01
  day: 01
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: Germany
– name: Heidelberg
PublicationTitle 3 Biotech
PublicationTitleAbbrev 3 Biotech
PublicationTitleAlternate 3 Biotech
PublicationYear 2023
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References NunesMCPlasmodium falciparum FIKK kinase members target distinct components of the erythrocyte membranePLoS One20105710.1371/journal.pone.0011747206685262909202
Arendse LB et al (2021) Plasmodium kinases as potential drug targets for malaria: challenges and opportunities. ACS Infect Dis
MnzavaAPMalaria vector control at a crossroads: public health entomology and the drive to eliminationTrans R Soc Trop Med Hyg2014108955055410.1093/trstmh/tru10125009173
BalajiSNSahasrabuddheAATrivediVInsulin signalling in RBC is responsible for growth stimulation of malaria parasite in diabetes patientsBiochem Biophys Res Commun202052835315371:CAS:528:DC%2BB3cXhtFSlu7nO10.1016/j.bbrc.2020.05.15432505351
LinBCFIKK Kinase, a Ser/Thr kinase important to malaria parasites, is inhibited by tyrosine kinase inhibitorsACS Omega2017210660566121:CAS:528:DC%2BC2sXhs1alur%2FE10.1021/acsomega.7b00997300235256044879
BatinovicSAn exported protein-interacting complex involved in the trafficking of virulence determinants in Plasmodium-infected erythrocytesNat Commun20178160441:CAS:528:DC%2BC2sXhtFClsbbP10.1038/ncomms16044286917085508133
WardPProtein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryoteBMC Genom200457910.1186/1471-2164-5-79
Nsanzabana C (2019) Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis 4(1).
Menard D, Dondorp A (2017) Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med 7(7).
VimeeRVirtual screening, molecular modelling and biochemical studies to exploit PF14_0660 as a target to identify novel anti-malarialsLett Drug Des Discov201916441742610.2174/1570180815666180727121200
Pousibet-PuertoJImpact of using artemisinin-based combination therapy (ACT) in the treatment of uncomplicated malaria from Plasmodium falciparum in a non-endemic zoneMalar J201615133910.1186/s12936-016-1408-1273681604930579
AK D et al (2021) Plasmodium falciparum FIKK9.1 is a monomeric serine-threonine protein kinase with features to exploit as a drug target. Chem Biol Drug Des.
HaldarKBhattacharjeeSSafeukuiIDrug resistance in PlasmodiumNat Rev Microbiol20181631561701:CAS:528:DC%2BC1cXhtl2msro%3D10.1038/nrmicro.2017.161293558526371404
DasSEvidence of artemisinin-resistant Plasmodium falciparum malaria in Eastern IndiaN Engl J Med2018379201962196410.1056/NEJMc171377730428283
MoxonCAGrauGECraigAGMalaria: modification of the red blood cell and consequences in the human hostBr J Haematol201115466706791:CAS:528:DC%2BC3MXhtlSks7rF10.1111/j.1365-2141.2011.08755.x216237673557659
TutejaRMalaria—an overviewFEBS J200727418467046791:CAS:528:DC%2BD2sXhtVyksL3L10.1111/j.1742-4658.2007.05997.x17824953
SiddiquiGProellochsNICookeBMIdentification of essential exported Plasmodium falciparum protein kinases in malaria-infected red blood cellsBr J Haematol202018857747831:CAS:528:DC%2BB3cXjvVWnuro%3D10.1111/bjh.1621931650539
RugMExport of virulence proteins by malaria-infected erythrocytes involves remodeling of host actin cytoskeletonBlood201412423345934681:CAS:528:DC%2BC2cXitV2nsbbP10.1182/blood-2014-06-583054251393484246041
DaviesHAn exported kinase family mediates species-specific erythrocyte remodelling and virulence in human malariaNat Microbiol2020568488631:CAS:528:DC%2BB3cXmvFymur4%3D10.1038/s41564-020-0702-4322845627116245
Organization W.H. (2020) World malaria report 2020: 20 years of global progress and challenges.
LinBCThe anthraquinone emodin inhibits the non-exported FIKK kinase from Plasmodium falciparumBioorg Chem2017752172231:CAS:528:DC%2BC2sXhs1aktL3M10.1016/j.bioorg.2017.09.01128987877
VijayanRSConformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitorsJ Med Chem20155814664791:CAS:528:DC%2BC2cXitVCku7rP10.1021/jm501603h25478866
3677_CR13
3677_CR15
BC Lin (3677_CR9) 2017; 75
J Pousibet-Puerto (3677_CR16) 2016; 15
H Davies (3677_CR6) 2020; 5
3677_CR10
MC Nunes (3677_CR14) 2010; 5
R Tuteja (3677_CR19) 2007; 274
P Ward (3677_CR22) 2004; 5
R Vimee (3677_CR21) 2019; 16
K Haldar (3677_CR7) 2018; 16
AP Mnzava (3677_CR11) 2014; 108
SN Balaji (3677_CR3) 2020; 528
M Rug (3677_CR17) 2014; 124
G Siddiqui (3677_CR18) 2020; 188
BC Lin (3677_CR8) 2017; 2
S Batinovic (3677_CR4) 2017; 8
CA Moxon (3677_CR12) 2011; 154
3677_CR1
3677_CR2
S Das (3677_CR5) 2018; 379
RS Vijayan (3677_CR20) 2015; 58
References_xml – volume: 15
  start-page: 339
  issue: 1
  year: 2016
  ident: 3677_CR16
  publication-title: Malar J
  doi: 10.1186/s12936-016-1408-1
  contributor:
    fullname: J Pousibet-Puerto
– volume: 5
  start-page: 79
  year: 2004
  ident: 3677_CR22
  publication-title: BMC Genom
  doi: 10.1186/1471-2164-5-79
  contributor:
    fullname: P Ward
– volume: 108
  start-page: 550
  issue: 9
  year: 2014
  ident: 3677_CR11
  publication-title: Trans R Soc Trop Med Hyg
  doi: 10.1093/trstmh/tru101
  contributor:
    fullname: AP Mnzava
– volume: 16
  start-page: 156
  issue: 3
  year: 2018
  ident: 3677_CR7
  publication-title: Nat Rev Microbiol
  doi: 10.1038/nrmicro.2017.161
  contributor:
    fullname: K Haldar
– volume: 379
  start-page: 1962
  issue: 20
  year: 2018
  ident: 3677_CR5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc1713777
  contributor:
    fullname: S Das
– volume: 5
  issue: 7
  year: 2010
  ident: 3677_CR14
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0011747
  contributor:
    fullname: MC Nunes
– volume: 58
  start-page: 466
  issue: 1
  year: 2015
  ident: 3677_CR20
  publication-title: J Med Chem
  doi: 10.1021/jm501603h
  contributor:
    fullname: RS Vijayan
– volume: 16
  start-page: 417
  issue: 4
  year: 2019
  ident: 3677_CR21
  publication-title: Lett Drug Des Discov
  doi: 10.2174/1570180815666180727121200
  contributor:
    fullname: R Vimee
– volume: 8
  start-page: 16044
  year: 2017
  ident: 3677_CR4
  publication-title: Nat Commun
  doi: 10.1038/ncomms16044
  contributor:
    fullname: S Batinovic
– volume: 2
  start-page: 6605
  issue: 10
  year: 2017
  ident: 3677_CR8
  publication-title: ACS Omega
  doi: 10.1021/acsomega.7b00997
  contributor:
    fullname: BC Lin
– ident: 3677_CR1
– volume: 528
  start-page: 531
  issue: 3
  year: 2020
  ident: 3677_CR3
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2020.05.154
  contributor:
    fullname: SN Balaji
– ident: 3677_CR15
– volume: 5
  start-page: 848
  issue: 6
  year: 2020
  ident: 3677_CR6
  publication-title: Nat Microbiol
  doi: 10.1038/s41564-020-0702-4
  contributor:
    fullname: H Davies
– volume: 274
  start-page: 4670
  issue: 18
  year: 2007
  ident: 3677_CR19
  publication-title: FEBS J
  doi: 10.1111/j.1742-4658.2007.05997.x
  contributor:
    fullname: R Tuteja
– volume: 154
  start-page: 670
  issue: 6
  year: 2011
  ident: 3677_CR12
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2011.08755.x
  contributor:
    fullname: CA Moxon
– ident: 3677_CR13
  doi: 10.3390/tropicalmed4010026
– volume: 188
  start-page: 774
  issue: 5
  year: 2020
  ident: 3677_CR18
  publication-title: Br J Haematol
  doi: 10.1111/bjh.16219
  contributor:
    fullname: G Siddiqui
– volume: 75
  start-page: 217
  year: 2017
  ident: 3677_CR9
  publication-title: Bioorg Chem
  doi: 10.1016/j.bioorg.2017.09.011
  contributor:
    fullname: BC Lin
– volume: 124
  start-page: 3459
  issue: 23
  year: 2014
  ident: 3677_CR17
  publication-title: Blood
  doi: 10.1182/blood-2014-06-583054
  contributor:
    fullname: M Rug
– ident: 3677_CR2
  doi: 10.1021/acsinfecdis.0c00724
– ident: 3677_CR10
  doi: 10.1101/cshperspect.a025619
SSID ssj0000515910
Score 2.2842207
Snippet The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing...
SourceID pubmedcentral
proquest
crossref
pubmed
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 277
SubjectTerms Agriculture
Antimalarial activity
Antimalarial agents
Antiparasitic agents
Binding
Bioinformatics
Biomaterials
Biotechnology
Calorimetry
Cancer Research
Chemistry
Chemistry and Materials Science
Enzyme inhibitors
Heterocyclic compounds
Kinases
Libraries
Life cycles
Malaria
Molecular interactions
Organelles
Organic compounds
Original
Original Article
Parasites
Plasmodium falciparum
Proteomes
Scaffolds
Stem Cells
Stoichiometry
Substrates
Survival
Titration
Titration calorimetry
Title Plasmodium falciparum FIKK 9.1 kinase modeling to screen and identify potent antimalarial agents from chemical library
URI https://link.springer.com/article/10.1007/s13205-023-03677-x
https://www.ncbi.nlm.nih.gov/pubmed/37476548
https://www.proquest.com/docview/2839383892
https://www.proquest.com/docview/2841023811
https://pubmed.ncbi.nlm.nih.gov/PMC10354315
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2x5QAXxDeBUhmJG3g3cZzYOVZtV0UVqBIgbU-R4w8R0SSrbha1_56xN9myVFy4RYklO5mx50087xngvXRCSKdTmhhuqBfoooXhmsYVz-MqdUlhPRv59Kv4spDHJ14mJx-5MKFoX1f1tL1spm39I9RWLhs9G-vEZuefj5I49RTubDaBCYLDP3L0QdE7K4IMAfM86UywxcCW2XDmUubr1VhKcfEWgnol6hRBtT9AfTc43UGcdwsn_9o9DUFp_hgeDWiSHG5G_QTu2fYpPBjJxqtn8Osc0XHTmXrdEKcufQH1FV7OP52dkWKakJ91i2GMhPNwsAfSdwTXEcxtiWoNqQOL192QZYfQusd7fd0ozIXRaYnypKwV8fwUogfZATL8FHoO3-cn345O6XDUAtUYonsqbeI1jpQT1kitLbNZYhhXmdWKOUyZChO7XHKjPLVHiEwbxVOnVVVlyrgsfQF7bdfaV0CsFSpJMehpKXjOC6m4UrHOuDAGwUoewYfxG5fLjaJGeaud7I1TonHKYJzyOoL90QzlMLtWJUKiAjNrWbAI3m0f47zwmx2qtd3at-FJwCNJBC83Vtt2N5o7Arljz20Dr7m9-wRdMWhvj64XwcfR9Lfj-vdrvP7_nt7AQxa81Rcd7sNef7W2b2GyMusDuH-4uLg4Pgj-_xvXSwgE
link.rule.ids 230,315,729,782,786,887,27933,27934,48344,48347,49649,49652,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_B9jD2wMeAERhgJN4gKI6d2HmsxkqrjgmJIu0tcv0BETSZ2hTBf8_ZTVqVwQO8RbGV2Oez786-388AL6UTQjrNYmq4iT1BV1wYruNkxvNkxhwtrEcjjz6Ki0v59szT5PAeCxOy3fsjybBSb8FuLPWJZimLcdUVIkbPcZ8XOUdd3h-Mp--Gm70Vf29JEYgIUo-UzkR62eFl_vyhXZt0zdG8ni_526FpsEXDO__Xi7twu_M9yWCtLPfghq2P4HDwedHxb9gjODjtL4DD5x60vLwP3z-glz1vTLWaE6e--UTsBT4Ox5MJKd5Q8rWq0RyScK8ONoe0DcH1CGNkompDqoAGdj_JVYMueovv2mquMKZG5SfKg7uWxONciO7oC0i3ufQAPg3PpqejuLuyIdZo6ttYWuq5kpQT1kitbWozalKuMqtV6jD0KkzicsmN8hAhITJtFGdOq9ksU8Zl7CHs1U1tHwGxVijK0HhqKTiOslRcqURnXBiDTk8ewat-0MqrNTNHueVg9lIuUcplkHL5I4KTflzLbpYuS3StCozQZZFG8GJTjFL2hyaqts3K1-E0-DU0guO1Gmx-xzAWyzHki0DuKMimgufu3i2pqy-Bw5smzLMQZBG87vVk266_d-Pxv1V_Dgej6fvz8nx8MXkCt9Kgdj558QT22sXKPoWbS7N61s2fX5hRFqo
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB5BV-Jx4LG8AgsYiRuEzcOJnWO1u2GrotVKLNLeItcPiKBJ1aYI_j0zaZKqLBwQtyi2Ens8tmfs-b4BeC2dENLp2A8NNz4RdPmZ4doPZjwNZrELM0to5NOP4uxSHp8QTc6A4m-j3fsryQ2mgViaquZwYdzhFvgWRxR0FsU-rsBC-GhF7tGxGB_B3nhy8T4fzlkoh0nWkhJEhJpORHTZYWf-_KHd_emK0Xk1dvK3C9R2X8rv_n-P7sGdziZl440S3YdrttqH2-PPy46Xw-7DzaM-MRw-92Dm1QP4fo7W97w25XrOnPpGAdpLfMwn0ynL3oXsa1nhNsnafDvYNNbUDNcp9J2ZqgwrW5Sw-8kWNTUV3zXlXKGvjZOCKQJ9rRjhX5juaA1Yd-j0ED7lJxdHp36XysHXaAI0vrQhcSgpJ6yRWtvIJqGJuEqsVpFDlywzgUslN4qgQ0Ik2igeO61ms0QZl8SPYFTVlX0CzFqhwhg3VS0FT3kmFVcq0AkXxqAxlHrwph_AYrFh7Ci23Mwk5QKlXLRSLn54cNCPcdHN3lWBJleGnrvMIg9eDcUoZbpMUZWt11SHh629E3rweKMSw-9i9NFSdAU9kDvKMlQgTu_dkqr80nJ7h0FM7ASJB297ndm26-_dePpv1V_CjfPjvPgwOZs-g1tRq3UU03gAo2a5ts_h-sqsX3RT6Rcn-h-D
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasmodium+falciparum+FIKK+9.1+kinase+modeling+to+screen+and+identify+potent+antimalarial+agents+from+chemical+library&rft.jtitle=3+Biotech&rft.au=Kumar%2C+D.+Anil&rft.au=Karjee%2C+Pallab&rft.au=Prasad%2C+M.+Rajendra&rft.au=Punniyamurthy%2C+Tharmalingam&rft.date=2023-08-01&rft.pub=Springer+International+Publishing&rft.issn=2190-572X&rft.eissn=2190-5738&rft.volume=13&rft.issue=8&rft_id=info:doi/10.1007%2Fs13205-023-03677-x&rft.externalDocID=10_1007_s13205_023_03677_x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-572X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-572X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-572X&client=summon